2023-04-07| R&D

New White Blood Cell Subtype as HIV Reservoir Identified

by Nai Ye Yeat
Share To

Scientists from Johns Hopkins University have identified myeloid cells, a subset of white blood cells including monocytes and macrophages, can act as HIV reservoirs in patients who have been virally suppressed for years on antiretroviral therapy (ART) and can be reactivated and infect new cells. 

Their novel findings, published in the journal Nature Microbiology, strongly suggest that myeloid cells could be another potential target in developing strategies to eradicate HIV.

Related Article: Fifth HIV Patient Cured After Stem Cell Transplant in Germany

The Limitations of Antiretroviral Therapy

Antiretroviral therapy is the standard treatment for HIV patients which combines two or more antivirals to increase potency and reduce the likelihood of the virus developing resistance. Despite ART showing its efficacy to control HIV progression, the virus may still exist in cells that are in a resting, or latent, state, creating an HIV reservoir. 

Among them, CD4 T cells are the most well-studied HIV reservoir. However, targeting CD4 T cells alone could not eradicate HIV, thus, Identifying more HIV reservoirs is critical to curing efforts, before latent HIV reactivation if people stop taking antiretroviral medications.

Monocytes are immune cells that circulate in the blood for about 3 days before traveling to tissue in various parts of the body, including the brain, where they can mature into macrophages. So far, there is no other evidence showing latent HIV in the short-lived monocytes and longer-lived monocyte-derived macrophages can become active again and infect other cells.  

Promising Target to Develop Antiviral Strategy

In the current study, the investigators measured HIV DNA in myeloid cells in a sample of 30 participants with HIV that were virally suppressed and had been on ART for at least 5 years. HIV genetic material in monocytes and macrophages was detected, though at a much lower level than those observed in CD4 T cells. 

They then isolated monocytes from blood samples taken from 10 participants and nurtured the monocytes in cultures that contained antiretroviral drugs, to replicate the participants’ baseline physical state. After the monocytes differentiated into macrophages, the researchers introduced an immune-activating agent and then added fresh white blood cells to allow for the virus to spread to new cells.  

At the end of the study, cultures collected from half of the participants had detectable HIV genetic material in monocyte-derived macrophages that could be reactivated to infect other cells and produce more virus, suggesting the myeloid cells are the reservoir for the virus to persist for years.

Overall, it may be said the myeloid cells would become the next focus of scientists to modify current ART, however, the investigators also pointed out their limitations in sample size and population diversity.

© All rights reserved. Collaborate with us:
Related Post
Fifth HIV Patient Cured After Stem Cell Transplant in Germany
Gilead Touts Long-Term Efficacy And Safety Data For HIV Drug
Merck’s Phase 2 HIV Treatment Study Resumes with Phase 3 Program Announcement
From Sweet to Risky: The Alarming Findings on Sucralose’s Genotoxicity
GHG Emissions as a ESG Metric
NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO’s Demo Day
Krystal Biotech’s First Topical Gene Therapy Approved by FDA
The Emergence of General AI for Medicine: Medical Applications of ChatGPT
Strengthening Genetic Screening Platform in APAC for Lung Cancer Precision Medicine: An Interview with Dr. Koichi Goto
2023 International Healthcare Week: Showcasing Emerging Competencies of Hong Kong’s Biomedical Industry
Scroll to Top